TipRanks
Advertisement
Advertisement

TRDA Stock Latest News

Entrada Therapeutics appoints Linea Aspesi as chief people officer
The FlyEntrada Therapeutics appoints Linea Aspesi as chief people officer
9h ago
TRDA
Entrada Therapeutics reports positive ENTR-601-45 trial results
PremiumCompany Announcements
Entrada Therapeutics reports positive ENTR-601-45 trial results
7d ago
8K
TRDA
Entrada Therapeutics reports data from Cohort 1 of ELEVATE-45-201 clinical study
PremiumThe Fly
Entrada Therapeutics reports data from Cohort 1 of ELEVATE-45-201 clinical study
7d ago
TRDA
Entrada Therapeutics price target raised to $11 from $10 at Roth Capital
PremiumThe Fly
Entrada Therapeutics price target raised to $11 from $10 at Roth Capital
2M ago
TRDA
Entrada Therapeutics reports Q2 EPS ($1.01), consensus ($1.04)
PremiumThe Fly
Entrada Therapeutics reports Q2 EPS ($1.01), consensus ($1.04)
3M ago
TRDA
Entrada Therapeutics Stockholders Approve Directors and Equity Plans
PremiumCompany AnnouncementsEntrada Therapeutics Stockholders Approve Directors and Equity Plans
4M ago
8K
TRDA
Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim
Premium
The Fly
Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim
5M ago
TRDA
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress
Premium
Company Announcements
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress
5M ago
8K
TRDA
Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital
PremiumThe Fly
Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital
6M ago
NVS
TRDA
Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
6M ago
TRDA
Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study
PremiumThe Fly
Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study
6M ago
TRDA
Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
PremiumRatings
Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
6M ago
TRDA
Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)
PremiumThe FlyEntrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)
6M ago
TRDA
Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data
Premium
Company Announcements
Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data
6M ago
8K
TRDA
Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer
Premium
The Fly
Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer
7M ago
TRDA
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
7M ago
TRDA
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
7M ago
TRDA
Entrada Therapeutics management to meet with Oppenheimer
PremiumThe Fly
Entrada Therapeutics management to meet with Oppenheimer
7M ago
TRDA
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
PremiumRatings
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
8M ago
TRDA
Entrada Therapeutics price target raised to $19 from $13 at Roth Capital
PremiumThe FlyEntrada Therapeutics price target raised to $19 from $13 at Roth Capital
8M ago
TRDA
Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)
Premium
The Fly
Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)
8M ago
TRDA
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
Premium
Ratings
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
8M ago
TRDA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >